This page shows the latest regorafenib news and features for those working in and with pharma, biotech and healthcare.
Meanwhile, NICE has decided to remove Bayer ’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the
Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with
The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the
Oral multikinase inhibitor Stivarga (regorafenib) has been cleared by the US regulator for patients with hepatocellular carcinoma (HCC) who have been previously treated with Bayer's older drug Nexavar (sorafenib).
Bayer nets speedy US review for regorafenib in liver cancer. Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales. ... Regorafenib - sold as Stivarga for colorectal and gastrointestinal stromal (GIST) tumours - has
Colorectal cancer and gastrointestinal stromal rumour (GIST) therapy Stivarga (regorafenib) disappointed however, with sales down 25% thanks to increased competition in the US, although Bayer is hoping to reinvigorate the product ... Initial results from
More from news
Approximately 8 fully matching, plus 35 partially matching documents found.
To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...